# HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study

## TL;DR

Hypothermic oxygenated machine perfusion (HOPE) treatment of liver grafts is linked to lower HCC recurrence and better survival in liver transplant recipients compared to non-perfused grafts.

## Contribution

First large international study showing HOPE reduces HCC recurrence and improves survival in liver transplants.

## Key findings

- HCC recurrence rate was 6.9% in HOPE-treated liver transplants.
- HOPE-treated HCC recipients had significantly better 5-year survival than non-perfused graft recipients.
- Survival in HOPE-treated HCC recipients was comparable to non-HCC recipients.

## Abstract

Liver transplantation (LT) for hepatocellular carcinoma (HCC) is performed worldwide, with 5-year survival rates of approximately 70%. However, post-transplant HCC recurrence occurs in 15-20% of recipients. We aimed to evaluate, for the first time, long-term recurrence-free survival in a large international cohort of patients undergoing LT for HCC using grafts treated with hypothermic oxygenated machine perfusion (HOPE).

This observational post hoc analysis of the multicenter European HOPE-REAL study (NCT05520320) included adult recipients with HCC (N = 599) who received a liver from either a donation after brain death (DBD) or donation after circulatory death (DCD) donor, preserved using HOPE, dual-HOPE (DHOPE), or normothermic regional perfusion followed by HOPE (NRP-HOPE) between 2012 and 2022. Propensity score matching was used to compare outcomes between HCC and non-HCC recipients within the HOPE-REAL cohort, and between HOPE-treated HCC recipients and an external control cohort receiving non-perfused livers (n = 484).

The overall HCC recurrence rate in the HOPE-REAL cohort was 6.9% (41/599), with no significant difference between DBD and DCD liver transplants (7.1% [25/350] vs. 6.4% [16/249]; p = 0.346). One-, 3-, and 5-year overall survival rates were 92%, 86%, and 81%, while recurrence-free survival rates were 90%, 83%, and 78%, respectively. Five-year overall survival was similar between 347 HOPE-treated HCC recipients (82%) and 347 matched non-HCC recipients (84%) (p = 0.625). In contrast, compared to an external cohort of 312 non-perfused HCC recipients, 5-year overall survival was significantly higher in 312 matched HOPE-treated HCC recipients (74% vs. 84%; p = 0.034).

HCC recurrence was rare after transplantation of livers treated with HOPE. Long-term survival in HOPE-treated HCC recipients was significantly better than in those receiving non-perfused livers, and comparable to outcomes in non-HCC recipients. These findings warrant validation in a randomized clinical trial.

This post hoc analysis of the HOPE REAL study demonstrates, for the first time, low hepatocellular carcinoma (HCC) recurrence rates in a large cohort of hypothermic oxygenated machine perfusion-treated liver transplant recipients with HCC, and significantly better survival outcomes compared to matched recipients of non-perfused grafts. These findings may have important implications, particularly as tumor-related indications for liver transplantation continue to rise. Machine liver perfusion could emerge as a novel strategy to improve oncological outcomes in high-risk cancer conditions after transplantation, potentially via mitigation of inflammation and reduced tumor cell seeding.

NCT05520320

Image 1

•HOPE treatment was identified as an independent significant protective factor against HCC recurrence.•Among patients with HCC, 5-year suvival and recurrence -free survival was higher in matched recipients of HOPE treated DBD grafts than non-perfused DBD grafts (84% vs. 74% and 77 vs. 67%, respectively).•In contrast, survival was not different between HOPE treated HCC recipients and matched non HCC recipients ( 82% vs 84% at 5 years).

HOPE treatment was identified as an independent significant protective factor against HCC recurrence.

Among patients with HCC, 5-year suvival and recurrence -free survival was higher in matched recipients of HOPE treated DBD grafts than non-perfused DBD grafts (84% vs. 74% and 77 vs. 67%, respectively).

In contrast, survival was not different between HOPE treated HCC recipients and matched non HCC recipients ( 82% vs 84% at 5 years).